Screener
Arcutis Biotherapeutics, Inc. ARQT Topical roflumilast program costs — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | $129,861 | $81,504 | $235,259 | $147,350 |
| Less: | ||||
| Cost of sales | 10,376 | 6,929 | 19,598 | 12,780 |
| Topical roflumilast program costs | 1,983 | 2,827 | 5,290 | 4,273 |
| ARQ-234 program costs | 1,302 | 845 | 12,305 | 2,034 |
| Other program costs | 102 | 1,193 | 197 | 2,375 |
| Research and development compensation and personnel-related expenses | 11,366 | 9,779 | 22,411 | 19,417 |
| Selling, general and administrative expenses | 82,008 | 69,033 | 155,962 | 132,917 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D?
- Arcutis Biotherapeutics, Inc. (ARQT) reported topical roflumilast program costs — R&D of $1.98M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D decreased by 29.9% year-over-year, from $2.83M to $1.98M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D?
- Over 2 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — R&D has grown at a -63.7% compound annual growth rate (CAGR), from $83.03M to $10.94M.
- What does topical roflumilast program costs — R&D mean?
- This metric represents the direct research and development expenditures specifically allocated to the topical roflumilast product pipeline. It captures the costs associated with clinical trials, regulatory filings, and formulation development required to advance this specific therapeutic candidate toward commercialization. Monitoring these costs helps investors assess the capital intensity and progress of the company's primary dermatological asset.
Ask your AI about Arcutis Biotherapeutics, Inc.'s topical roflumilast program costs — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude